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ABSTRACT 
RMI  14,  514 ([5-tetradecycloxy]-2-furancarboxylic  acid) represents a  new class 
of hypolipidemic agents which cause unusual ultrastructural changes in liver of 
male rats and in selected peroxisomal enzymes in liver and kidney of both sexes. 
Among the principal ultrastructural changes in peroxisomes of male rat liver were 
(a) cavitation and compartmentalization of the matrix, often giving the appear- 
ance of a peroxisome-within-a-peroxisome, and (b) narrow, dense extensions of 
canaliculi  or  cisterns  from  the  periphery  of the  peroxisome,  forming partial 
circlets or  surrounding irregular areas of cytoplasm. The  unusual  enzyme re- 
sponses were (a) elevation of catalase activity in liver and kidney in female rats, 
(b)  increased  activity  of  three  hydrogen peroxide-producing  oxidases  (urate 
oxidase, L-a-hydroxy acid oxidase, and o-amino acid oxidase) in the liver of both 
sexes, and (c) elevation of activity of the last two oxidases in male kidney. The 
peculiar ultrastructural changes in liver peroxisomes combined with the responses 
of selected peroxisomal enzymes represent unusual modulations or adaptations of 
these organelles to  a  hypolipidemic agent, the effects of which have not been 
reported extensively. 
KEY  WORDS  peroxisomes  liver  kidney  ￿9 
hypolipidemia  RMI 14,514  oxidases 
The  proliferation  of  peroxisomes,  especially  in 
male  rat or mouse  liver, after administration of 
Clofibrate (CPIB, ethyl-ct-p-chlorophenoxyisobu- 
tyrate;  Ayerst  Laboratories,  New  York)  (23, 
24,  42)  or  other  hypolipidemic  drugs  with 
chemical  structure  similar to  that  of  Clofibrate 
(12,  47)  or  to  that  of  hypolipidemic  drugs 
unrelated  to  Clofibrate  (37),  has  been  amply 
documented. Characteristically, in the absence of 
other drugs that bind catalase or inhibit its synthe- 
sis,  the  proliferation  of  hepatic  peroxisomes  is 
accompanied by a simultaneous increase in activ- 
ity of catalase, one  of the  principal enzymes of 
these organelles, and by a variety of subtle mor- 
phological alterations such  as  absence  of a  nu- 
cleoid, changes in matrix density, appearance of 
matrix tubules or striations, marginal plates, and 
elongated profiles. 
One purpose of this paper is to report unusual 
ultrastructural  abnormalities  in  hepatic  peroxi- 
somes of male rats given RMI  14,514  ([5-tetra- 
decycloxy]-2-furancarboxylic acid)  (Fig.  1).  The 
principal ultrastructural abnormalities of hepatic 
peroxisomes illustrated in this paper are peculiar 
and  have  not  been  reported  previously, to  our 
knowledge. RMI  14,  514  represents a  new class 
of drugs which produce hypolipidemic effects in 
810  J. CELL BIOLOGY ￿9  The Rockefeller University Press ￿9 0021-9525/78/0901-081051.00 0  H29c40  c02H 
FIGURE  I 
rats  and  monkeys.  In  rats,  the  drug  produces 
marked  reduction  in  plasma cholesterol and  tri- 
glyceride  levels  and  reduces  hepatic  fatty  acid 
synthesis to  one-third of control levels. Hepato- 
megaly and effects on liver fat are less than after 
Clofibrate treatment. RMI 14, 514 is reported to 
be  more  effective  than  Clofibrate  in  reducing 
plasma cholesterol levels, whereas plasma triglyc- 
erides  are  reduced  to  approximately  the  same 
degree by CPIB  and  RMI  14,  514.  Preliminary 
studies indicate that RMI 14,514 not only differs 
from  Clofibrate  and  its  aryloxyisobutyrate ana- 
logues in chemical structure but also in its proba- 
ble mechanism of action (18,  32,  33).  RMI  14, 
514 also differs in chemical configuration from the 
novel hypolipidemic, non-Clofibrate-like drugs (ti- 
bric  acid,  Wy  14643)  reported  by  Reddy  and 
Krishnakantha  (37)  to cause peroxisomal prolif- 
eration and increased catalase activity in liver cells 
of rats and mice. 
The  second purpose of this paper is to report 
certain changes in activity of selected peroxisomal 
enzymes that  occur in hepatic and  renal cells in 
rats given RMI 14,514, changes that differ from 
behavior of these enzymes after administration of 
other  hypolipidemic agents  of  various  chemical 
configurations  and  modes  of  action.  Early  bio- 
chemical studies indicated that peroxisomes con- 
tained not only catalase but also urate oxidase, D- 
amino  acid  oxidase,  L-a-hydroxy  acid  oxidase, 
and  isocitrate dehydrogenase  (4,  25).  With few 
exceptions (14), despite the characteristic increase 
in  hepatic  peroxisomes  and  catalase  activity  in 
male rats given Clofibrate, some of the oxidases 
of  hepatic  peroxisomes,  notably  D-amino  acid 
oxidase, urate oxidase and L-a-hydroxy acid oxi- 
dase  (in  those  instances in  which  these  enzymes 
were studied), remained unchanged or decreased 
significantly (2,  8,  9,  10,  11,  24,  28,  44).  In 
contrast,  after  animals are  given  RMI  14,  514, 
there is significant elevation in urate oxidase, L-a- 
hydroxy acid oxidase, and D-amino acid oxidase in 
the liver of both males and females (Table I) and, 
moreover,  activity of the  latter two  oxidases in- 
creases in kidneys of males (Table III), an obser- 
vation not previously reported. Although the ele- 
vation  of  catalase  activity  and  peroxisome  re- 
sponse in male rat liver after RMI 14,514  treat- 
ment is not unexpected in view of similar findings 
with several other hypolipidemic drugs, the spec- 
trum of other changes produced by RMI 14,514, 
namely  (a)  the  ultrastruetural  abnormalities  in 
hepatic peroxisomes, (b) the elevation of catalase 
activity in female rat liver and kidney, and (c) the 
increased activity of three hydrogen peroxide-pro- 
ducing oxidases in liver of both sexes and of two 
peroxisomal oxidases in  male rat kidney, consti- 
tutes unusual adaptations of peroxisomes and adds 
to  the  currently  available  knowledge  regarding 
various modulations of these organelles to experi- 
mental manipulations. 
MATERIALS  AND  METHODS 
F-344 rats of both sexes weighing between  126 and 140 
g  were  housed  in  individual  cages,  given  water  and 
Purina Rat Chow (Ralston Purina Co., St. Louis., Mo.) 
ad lib., and weighed daily. RMI 14,514, obtained from 
Merrell-National  Laboratories, Cincinnati,  Ohio,  was 
suspended  in  ethyl  alcohol  and given by gavage each 
morning at 8 a.m. at a dose of 150 mg/kg body weight 
once  a day for 7 successive days. Control rats of both 
sexes were given equal amounts of alcohol without RMI 
14,514 by daily gavage. At 10 a.m. on the 7th day, the 
animals were  sacrificed,  the livers were  weighed,  and 
samples  of liver, kidney, and  intestinal  mucosa  were 
taken from each animal for biochemical and ultrastruc- 
rural study. 2 ml of blood were collected from the aorta 
of 13 control and five experimental  animals of each sex 
for determination of triglycerides, cholesterol, and pro- 
teins. The number of control and experimental animals of 
each sex used for study of liver and kidney is indicated in 
Tables I and III, respectively. Because a previous study 
from  this laboratory had shown that Clofibrate  caused 
significant increase in microperoxisomes and in catalase 
activity in the mucosa of jejunum and ileum of male rats 
and, to a lesser extent, in the jejunal mucosa of female 
rats (41),  samples of mucosa from jejunum and ileum 
were taken from nine control and five experimental rats 
of each sex to compare the effect of RMI 14, 514 to that 
of Clofibrate on intestinal catalase activity. Pure samples 
of mucosa were prepared and confirmed by light micros- 
copy as previously described (41). 
Biochemical and Electron 
Microscope Methods 
For measurement of catalase activity, samples of liver, 
intestinal mucosa, and kidney were homogenized in M/ 
150  phosphate buffer  at  1~176  in a  Potter-Elvehjem 
homogenizer  (Potter Instrument  Co.,  Inc., Plainview, 
N.Y.) in a 1:10 or 1:20 dilution.  Catalase  activity was 
measured  by the  spectrophotometric  method of LOck 
(27).  Total protein in liver, kidney,  intestinal mucosa, 
and serum were determined by the Lowry method (26). 
Serum  triglycerides were  measured  by the  method of 
DONALD  J.  SVOBODA Hepatic  and Renal Peroxisomes with RMI 14, 514  $11 t
~
 
e
*
 
T
A
B
L
E
 
!
 
E
f
f
e
c
t
s
 
o
 
f
 
R
M
1
1
4
,
5
1
4
"
 
o
n
 
F
-
3
4
4
 
R
a
t
 
L
i
v
e
r
 
<
 
O
o
 
~
D
 
M
a
l
e
 
C
o
n
t
r
o
l
 
E
x
p
e
r
i
m
e
n
t
a
l
 
C
h
a
n
g
e
 
N
o
.
 
N
o
.
 
r
a
t
s
 
L
i
v
e
r
 
r
a
t
s
 
L
i
v
e
r
 
P
 
v
a
l
u
e
 
%
 
F
e
m
a
l
e
 
C
o
n
t
r
o
l
 
E
x
p
e
r
i
m
e
n
t
a
l
 
C
h
a
n
g
e
 
N
O
.
 
N
o
.
 
r
a
t
s
 
L
i
v
e
r
 
r
a
t
s
 
L
i
v
e
r
 
P
 
v
a
l
u
e
 
%
 
O
0
 
%
 
t
i
s
s
u
e
 
w
t
/
b
o
d
y
 
w
t
 
1
5
 
3
.
4
 
+
-
-
 
0
.
1
 
9
 
C
a
t
a
l
a
s
e
 
(
U
/
r
a
g
 
p
r
o
t
e
i
n
)
 
1
5
 
3
6
.
9
 
-
+
 
1
.
0
 
9
 
U
r
i
c
a
s
e
 
(
U
/
r
a
g
 
p
r
o
t
e
i
n
)
 
I
0
 
1
.
9
 
-
.
+
 
0
.
1
 
9
 
a
-
H
y
d
r
o
x
y
 
a
c
i
d
 
o
x
i
d
a
s
e
 
(
U
/
h
/
r
a
g
 
1
0
 
0
.
1
2
 
-
 
0
.
0
0
6
 
9
 
p
r
o
t
e
i
n
)
 
D
-
A
m
i
n
o
 
a
c
i
d
 
o
x
i
d
a
s
e
 
(
U
/
h
/
m
g
 
p
r
o
t
e
i
n
)
 
1
0
 
0
.
2
3
 
•
 
0
.
0
1
 
9
 
l
i
p
i
d
s
 
(
%
/
g
 
w
e
t
 
t
i
s
s
u
e
)
 
6
 
4
.
3
 
•
 
0
.
6
 
5
 
3
.
9
 
•
 
0
.
1
 
>
0
.
0
0
5
 
7
7
.
1
 
•
 
3
.
3
 
>
0
.
0
0
1
 
3
.
5
 
+
-
-
 
0
,
2
 
>
0
.
0
0
1
 
0
.
2
1
 
•
 
0
.
0
2
 
>
0
.
0
0
1
 
0
.
5
0
 
~
 
0
.
0
4
 
>
0
.
0
0
1
 
2
.
5
 
•
 
0
.
2
 
>
0
.
0
2
5
 
+
1
5
 
1
4
 
3
.
4
 
•
 
0
.
1
4
 
1
0
 
3
.
9
 
-
+
-
 
0
.
0
7
 
>
0
.
0
1
 
+
1
5
 
+
1
0
9
 
1
4
 
2
9
.
6
 
•
 
1
.
3
 
1
0
 
5
6
.
7
 
•
 
3
,
1
 
>
0
.
0
0
1
 
+
9
2
 
+
8
4
 
9
 
2
.
1
 
•
 
0
.
1
 
I
0
 
3
.
5
 
•
 
0
.
2
 
>
0
.
0
0
1
 
+
6
7
 
+
7
5
 
9
 
0
.
0
6
 
•
 
0
.
0
0
5
 
1
0
 
0
.
0
9
 
-
-
-
 
0
.
0
0
6
 
>
0
.
0
0
5
 
+
5
0
 
+
1
1
7
 
9
 
0
.
2
3
 
-
+
 
0
.
0
2
 
1
0
 
0
.
4
3
 
•
 
0
.
0
4
 
>
0
.
0
0
1
 
+
8
7
 
-
4
2
 
6
 
4
.
7
 
-
+
 
0
.
4
 
5
 
3
.
0
 
~
-
 
0
.
3
 
>
0
.
0
1
 
-
3
6
 
*
 
1
5
0
 
m
g
/
k
g
/
d
a
y
 
f
o
r
 
7
 
d
a
y
s
,
 
b
y
 
g
a
r
a
g
e
.
 Fletcher (7). Urate oxidase activity was assayed by the 
method  of Arima and  Nose  (1),  and  D-amino  acid 
oxidase  and  L-a-hydroxy  acid  oxidase  activities  were 
assayed by the method of Robinson et al. (39). For total 
liver lipids, liver was dried to constant weight, extracted 
with Bloor's ethanol-ether solvent, then weighed again, 
and  the  lipid content  was  determined  by difference. 
Serum  cholesterol  was determined by the  method of 
Huang et al. (17). 
For routine  electron microscopy,  small  samples  of 
tissue were fixed in 2% osmium tetroxide buffered with 
S-collidine, and then dehydrated through a graded series 
of alcohols and propylene oxide. They were embedded 
in Epon, and ultrathin  sections were stained with lead. 
Semithin  (0.5  /.tm) sections of Epon-embedded tissues 
were  stained with basic fuchsin-crystal violet after re- 
moval of the Epon with sodium methoxide. For cyto- 
chemical  demonstration  of the  peroxidatic activity of 
catalase, samples of liver, kidney, and intestinal mucosa 
were  processed  according to the methods  of Novikoff 
and Goldfischer (29).  Controls  consisted of: (a) prein- 
cubation  for  15  min  in  propanedioi buffer containing 
0.02 M 3-amino-1,2,4-triazole  followed by incubation in 
standard Diaminobenzidine (DAB) medium also contain- 
ing 0.02 M aminotriazole, (b) preincubation for 10 rain in 
propanediol buffer containing 0.1 M KCN followed by in- 
cubation in the standard  DAB mixture also containing 
0.1  M KCN, and (c)  incubation in the standard  DAB 
incubation mixture lacking hydrogen peroxide. 
RESULTS 
Biochemical 
The results of enzyme assays on liver are given 
in Table I. It is apparent that RMI 14,514 caused 
significant increase in catalase activity in livers not 
only in male rats but in intact females as well. The 
percentage increase in catalase activity in experi- 
mental animals compared to controls was 109 and 
92% in males and females, respectively. Similarly, 
there was significant increase in activity of uricase, 
L-a-hydroxy acid oxidase and  D-amino acid oxi- 
dase in both sexes. There was a slight increase in 
liver weight (15%)  in both sexes given RMI  14, 
514.  Total liver lipids decreased slightly more in 
males than in females. 
The results for serum cholesterol, triglycerides, 
and  proteins  are  given  in  Table  II,  where  it  is 
apparent  that  there  was  significant  lowering  of 
serum  triglycerides,  due  to  RMI  14,  514,  in 
females.  There  was  a  slight  decrease  in  serum 
cholesterol  in  both  sexes  but  it  was  not  of the 
same  magnitude as the decrease in triglycerides. 
The changes in serum triglycerides and cholesterol 
are consistent with previous reports on the use of 
this agent (18, 32). 
The  results  of  assay  of  activities  of  selected 
renal peroxisomal enzymes are given in Table III, 
where it is evident that, in males, not only catalase 
but L-a-hydroxy acid oxidase activity and D-amino 
acid oxidase activity increased significantly. RM! 
14,  514 also caused significant elevation in renal 
catalase and  D-amino acid oxidase activity in fe- 
males.  There  was  no  significant change  in  L-a- 
hydroxy acid oxidase in females. 
The catalase activity of jejunal and ileal mucosa 
of male  and  female  rats  did not  change  signifi- 
cantly after  7  days of RMI  14,  514.  In control 
males, the catalase activity (in units per milligram 
of protein) in jejunum and ileum was 0.65  -  0.02 
and  0.78  -+  0.04,  respectively.  The  values  in 
experimental  males  were  0.77  -+  0.06  in  the 
jejunum and  1.21  -+ 0.2 in the ileum. In control 
females, the catalase activity in jejunum and ileum 
was  0.90  -+  0.08  and  0.93  -+  0.08,  whereas  in 
experimental females the values for jejunum and 
ileum,  respectively, were 0.91  +  0.09  and  1.16 
-+ 0.16. 
Morphological 
Ultrastructural  abnormalities  in  peroxisomes 
were observed only in  the  liver. Peroxisomes in 
kidney and in intestinal mucosa appeared normal 
in size and structure, though they were increased 
in number in renal tubular epithelium. 
Although the mean diameter of hepatic peroxi- 
somes in experimental animals was 0.3-0.5  /zm, 
several reached a diameter of 0.9/zm. Abnormal- 
ities in peroxisomes were present in all zones of 
the hepatic lobule and were not confined to any 
specific region of individual ceils. At low magnifi- 
cations, the most characteristic change in peroxi- 
somes  was  the  presence  of  irregularly  shaped 
cavities or defects in their matrix (Fig. 2). In some 
instances, peroxisomes contained a dense core in 
their matrix  (Fig. 3),  hut  many lacked a  typical 
crystalline  nucleoid.  At  higher  magnifications, 
many peroxisomes contained, in addition to cavi- 
ties, one or more circular compartments partially 
hut distinctly separated from the remaining matrix 
by condensations of matrix material surrounded 
by a limiting membrane, in some instances (Figs. 
3  and 4).  Occasionally, the material in the com- 
partments was surrounded by a relatively electron- 
transparent halo (Figs. 4  and 5). In most peroxi- 
somes,  in  addition  to  matrix  compartments  or 
cavities, there extended, from the periphery of the 
organelle,  narrow  linear  densities  coursing 
through adjacent cytoplasm and enclosing partial 
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 Fmu~  2  Several  peroxisomes  (Px)  contain  circular or irregularly shaped  cavities in  their  matrix. 
x  22,800. All illustrations are from sections of liver stained with lead. All bars, 0.5/zm. 
or  complete  circlets  (Figs.  5,  6,  9,  and  10).  In 
many  peroxisomes,  the  cavities  were  large  and 
eccentric, leaving most of the circumference of the 
organelle consisting of a narrow attenuated band 
of  material  of a  density  similar  to  that  of  the 
matrix  (Figs.  7  and  8).  The  cavities  contained 
filamentous (Fig. 7) or amorphous (Fig. 8) mate- 
rial  similar  to  surrounding  hyaloplasm.  In  some 
instances,  the  peroxisomes,  save  for  a  small 
amount  of matrix,  consisted  of several  linear  or 
narrow,  membrane-bounded canaliculi extending 
into and enclosing portions of cytoplasm (Fig. 8, 
open arrowhead, and Fig. 9, Px 3). In many cells, 
the  cavities surrounded  a  second circular matrix 
body,  giving  the  appearance  of  peroxisome- 
within-a-peroxisome (Fig.  10). In such instances, 
the  inner  matrical  mass  appeared  membrane 
bounded.  Similarly,  the  interior  aspect  or space 
within which the smaller matrical mass was located 
was confined by a  membrane.  Such changes may 
represent a more advanced stage of the alterations 
illustrated  in Figs.  3  and 4.  No marginal  plates, 
matrix striations,  or circumferential "budding" of 
peroxisomes was seen. Cytochemical preparations 
demonstrating the peroxidatic activity of catalase 
confirmed  the  identity  of  peroxisomes  in  their 
varied  configurations,  hut  ultrastructural  details 
illustrated  were  clearer with primary osmium te- 
troxide  fixation.  A  slight  increase  in smooth en- 
doplasmic reticulum was apparent.  No mitochon- 
drial alterations were observed. 
DISCUSSION 
Several studies have reported that peroxisomes are 
associated with or involved in lipid  metabolism in 
rodents  (13,  16,  23,  24,  31,  37,  42).  More 
recently,  Sternlieb  and  Quintana  (40)  observed 
that peroxisomes may enlarge or undergo changes 
in  electron  opacity  of the  matrix  in  association 
with the steatosis characteristic of early stages of 
Wilson's disease, suggesting that, in humans also, 
peroxisomes may be associated with lipid  metab- 
olism.  Though  RMI  14,514  differs  in  chemical 
structure and mode of action from hypolipidemic 
agents  reported  thus  far,  its  profound  effects, 
especially on hepatic peroxisomes, provide further 
evidence for a  relationship between peroxisomes 
and lipid metabolism, regardless of the nature of 
the hypolipidemic chemical. 
Studies with RMI 14,514 add to the increasing 
evidence for the heterogeneity of peroxisomes not 
only in their morphological alterations but also in 
their  enzymatic  responses  to  different  drugs,  in 
different tissues and in different sexes. For exam- 
ple,  there  are  obvious  differences  between  the 
effects of RMI 14,514 and Clofibrate on peroxi- 
somal enzymes. Catalase activity does not increase 
in the liver of female rats given 0.25% Clofibrate 
in  their  diet  unless  they are  castrated  and  given 
testosterone  (43),  whereas with  RMI  14,514 in- 
tact females showed a  significant increase  in he- 
patic catalase activity comparable to that occurring 
in  males  given  the  same  dose.  Reddy  et  al. 
reported an increase  in hepatic catalase  in intact 
females given Nafenopin, an analog of Clofibrate 
(36).  In  that  study,  however,  the  activities  of 
other peroxisomal oxidases were not investigated. 
The significant elevation of hepatic  uricase,  L-a- 
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both sexes given RMI 14,514 also differs from the 
usual response of these enzymes to Clofibrate or 
to other hypolipidemic drugs in  that,  instead of 
decreasing or remaining unchanged,  their activi- 
ties increased significantly in both sexes. Whether 
in female rats the metabolism of RMI  14,514  is 
different from the metabolism of other hypolipi- 
demic drugs has yet to be determined. 
Little has been reported on the effects of Clofi- 
brate or other hypolipidemic drugs on renal per- 
oxisomes and their enzymes. In an early report, 
Svoboda  et  al.  (44)  noted  only  slight  increase 
in  male  rat  renal  peroxisomes  after  8-10  wk 
of  Clofibrate  treatment.  Reddy  et  al.  (38), 
using methyl clofenapate, found marked prolifer- 
ation  in  renal  peroxisomes in  male  (wild  type) 
mice, but catalase activity was elevated <30%. In 
view of the paucity of information regarding the 
response of L-a-hydroxy acid oxidase and D-amino 
acid oxidase in rat kidneys after administration of 
more familiar hypolipidemic agents, it is impossi- 
ble to compare the renal peroxisomal response to 
RMI  14,514  in  kidneys of male rats with other 
data. In animals, the catalase activity of kidney is 
usually lower than that of liver, and the same is 
true after RMI 14,514 treatment. 
Another  difference  between  Clofibrate  and 
RMI 14,514 is their contrasting effect on intestinal 
mucosal catalase activity. After Clofibrate treat- 
ment, the jejunal and ileal mucosal catalase activ- 
ity in males increased 82  and  92%,  respectively 
(41),  whereas after RMI  14,514  treatment, nei- 
ther sex responded in terms of intestinal catalase 
activity. It is apparent that the same mechanisms 
may  not  influence  peroxisomal functions  or re- 
sponse in different tissues or in different sexes. 
Although elevations in hepatic peroxisomal ur- 
ate oxidase and o-amino acid oxidase after RMI 
14,514  administration are unusual,  they are not 
unique  to  this chemical. Hruban  et al.  reported 
elevation of hepatic urate  oxidase  and  o-amino 
acid oxidase in livers of male rats given W-1372 
(N- [benzyloxy]-N-3  [phenylpropyl]acetamide)  and 
1-benzylimidazole,  two  compounds  affecting 
blood cholesterol, as well as in rats given cyclizine 
derivatives (14). Urate oxidase is localized in the 
core or the nucleoid of peroxisomes (3, 45), and 
the nucleoid has been reported to increase in size 
in the peroxisomes of liver in rats given azaserine 
(15) or terephthalanalides (16).  Despite the ele- 
vation of hepatic urate oxidase activity after RMI 
14,514,  no increase in the size of nucleoids was 
seen. 
A  number  of  ultrastructural  abnormalities  in 
hepatic peroxisomes in rats given a wide variety of 
compounds  intended  to  alter the  metabolic sys- 
tems  of  peroxisomal  enzymes  was  reported  by 
Hruban et al. (16), and the spectrum of morpho- 
logic changes in hepatic peroxisomes in humans 
was  compiled  and  illustrated  by  Sternlieb  and 
Quintana  (40)  and  by Novikoff et al.  (30).  De- 
spite  some  similarities, none  of the  changes  in- 
cluded in these comprehensive reports were iden- 
tical  to  those  occurring  in  hepatic  peroxisomes 
after  RMI  14,514  treatment.  Close  structural 
relationships  and  continuities  between  peroxi- 
somes  and  the  smooth  endoplasmic  reticulum 
have  been  observed by several investigators (6, 
19, 25, 30, 46), and it has been hypothesized that 
peroxisomes may form condensations within local- 
ized outpocketings of cisterns of the smooth en- 
doplasmic reticulum (5, 35). Moreover, Poole et 
al. suggested that peroxisomes might not exist as 
FIGURE 3  Two peroxisomes contain matrix cavities or compartments. In Px 1, there is a dense core and 
two matrix compartments (solid arrowheads);  the one to the left appears limited by a membrane. In Px 2, 
there are two cavities containing amorphous material, and one compartment (solid arrowhead) containing 
material of density similar to that of the matrix, x  44,600. 
FIGURE 4  Px 1  contains a core of a density slightly greater than that of the surrounding  matrix and a 
cavity (solid arrowhead) containing  circular structures.  Px 2  contains  two compartments  of matrixlike 
density (solid arrowheads) surrounded by a halo of relative electron transparency.  ￿  44,600. 
FIGURE 5  Px 1  contains both a cavity and a compartment containing matrix-like material. Px 2  has a 
small, eccentric  cavity. A  narrow, dense  band or canaliculus extends from  it into the cytoplasm  and 
encloses a circlet at its terminus.  Px 3  also has a compartment and a protuberant circlet at its upper 
periphery, x  31,800. 
FXGURE 6  Px 1 has a large, electron-transparent cavity and two irregular extensions at the upper part of 
its profile. Px 2 has a bandiike linear extension that extends from the periphery to enclose a small portion 
of cytoplasm, x  31,800. 
DONALD J.  SVOBODA Hepatic and Renal Peroxisomes with RMI 14, 514  817 FIGURE 7  Px 1 illustrates  two peroxisomes with large eccentric cavities containing filamentous material. 
Most of the circumference consists of an attenuated band of material having a density similar to that of the 
matrix. Px 2 illustrates  two peroxisomes with matrix cavities. The circular, linear density (open arrowhead) 
may represent  a  cistern of endoplasmic reticulum containing peroxisome matrix or the periphery of a 
peroxisome whose major matrical portion is out of the plane of section, x  45,600. 
FIGURE  8  PX  1  and  Px  2  contain  large  cavities  containing  amorphous  material.  The  peroxisome 
indicated by the open arrowhead has an irregularly shaped matrical portion from which  extend several 
membrane-bounded, dense canaliculi enclosing several portions of cytoplasm. ￿  45,600. 
818  THE  JOURNAL OF  CELL BIOLOGY" VOLUME 78,1978 FIGURE  9  Px 1 and Px 2 contain small, dense cores and matrix cavities. Px 3 has linear, dense canaliculi 
extending from it (large open arrowhead) and partially enclosing a small circular peroxisome-like structure 
to the left. The small open arrowhead indicates a similar canaliculus  or cistern in close proximity to Px 3. 
x  31,800. 
FIOtrRE 10  Px 1,2,  and 3, though of differing diameter in this plane, each contain a small  circular, 
membrane-bounded compartment containing material of a  density similar  to  that  of the  matrix  and 
imparting a peroxisome-within-a peroxisome appearance. ￿  31,800. 
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of specialized portions of endoplasmic reticulum, 
with their protein components constituting a single 
common pool within which there is rapid continu- 
ous or intermittent  exchange (34).  Furthermore, 
to quote de Duve, "to mention an extreme possi- 
bility,  it  is  not  inconceivable  that  peroxisomes 
form in each cell a single membrane-bound space, 
of highly contorted and possibly continually vary- 
ing  shape,  associated  with  a  special  ER  region 
engaged in the manufacturing of the protein con- 
stituents"  (5).  With these  observations in mind, 
the narrow, dense canaliculi that extend from the 
periphery of some peroxisomes into, and partially 
or  totally  surround  portions  of,  cytoplasm  and 
form circlets (Figs. 5, 6, 8, and 9) may represent 
"flow"  or  "exchange"  of  peroxisomal  proteins 
within narrow cisterns of the smooth endoplasmic 
reticulum, inasmuch as the density of such exten- 
sions  resembles  that  of peroxisome  matrix  and 
these extensions appear to be continuous with the 
parent matrix via the narrow channels or canalic- 
uli.  If such  were  the  case,  it  would appear  that 
one  of the possible  effects of RMI  14,514  is to 
induce profound perturbations  in the cisterns of 
the smooth endoplasmic reticulum associated with 
peroxisomes or in the process of protein exchange 
occurring between peroxisomes and smooth ER. 
Aside from the narrow, dense channels extend- 
ing from peroxisome matrix, the other abnormali- 
ties consisted principally of (a) cavitation or de- 
fects of the matrix, (b) formation of one or more 
compartments in the matrix, or (c) the appearance 
of a targetlike peroxisome-within-a-peroxisome. It 
is not certain whether these abnormalities repre- 
sent primary modulations in the smooth endoplas- 
mic reticulum and consequent interference in nor- 
mal  processes  of synthesis  and  assembly  in  the 
morphogenesis  of peroxisomes  or  whether  they 
represent  injury  to  or  degenerative  changes  in 
previously  normal  peroxisomes.  The  relatively 
short half-life of hepatic peroxisomes (-1.5 days) 
would permit  interference  with  normal morpho- 
genesis  during  the  7  days  in which the  animals 
were given RMI 14,514. The relative scarcity of 
normal  peroxisomes in  any hepatic  cells  after  7 
days further suggests continuous interference with 
their normal formation or assembly. Serial studies 
with  daily or more frequent  sacrifice  of animals 
after short intervals on the drug might clarify this 
problem.  The  studies  of Poole  et  al.  indicating 
that peroxisomes are destroyed in a random fash- 
ion, with an older organelle no more likely to be 
destroyed at any given time than a younger one 
(35), indicate that structural abnormalities in per- 
oxisomes need not reflect  an age-dependent de- 
generation or injury. 
Hruban et al. described "gastruloid" cisterns as 
special  forms  of smooth  endoplasmic  reticulum 
(reference 14, Fig. 31, diagrams D and E) consist- 
ing of a double-walled loop with an inner pair of 
concentric rings which bears some resemblance to 
Fig.  10.  Without careful  and  extensive  study of 
consecutive  serial  sections,  it  is  impossible  to 
formulate  conclusive  evidence  for  the  three-di- 
mensional  dynamics  of  such  an  appearance  of 
"gastruloid"  cisterns or the peroxisome-within-a- 
peroxisome effect as seen  after  RMI  14,514  ad- 
ministration.  Their curious appearance  may rep- 
resent  in  situ  synthesis  of  peroxisomal  matrix 
proteins within concentric cisterns of the smooth 
endoplasmic  reticulum.  The  fact  that  both  the 
inner matrical mass and the interior aspect of the 
space  in  which  it  was  located  were  both  mem- 
brane-bounded suggests assembly of matrical pro- 
tein  simultaneously  in  concentric  or  connected 
cisterns  of  the  smooth  endoplasmic  reticulum. 
Alternatively, the appearance of compartments or 
targetlike  peroxisomes  may  represent  sections 
through invaginations or indentations into spheri- 
cal peroxisomes. 
Among the most significant and original obser- 
vations on peroxisomes and their relationship  to 
lipid metabolism are the recent reports by Laza- 
row  and  de  Duve  (21)  and  by  Lazarow  (20). 
Lazarow and  de  Duve indicated  that  fatty acyl- 
CoA oxidizing activity is present in rat liver per- 
oxisomes  and  increases  significantly  with  treat- 
ment of the rats with Clofibrate. There was simul- 
taneous increase in the number of hepatic peroxi- 
somes  (21).  Also,  Lazarow  demonstrated  that, 
like Clofibrate, tibric acid and Wy-14,643, given 
to male rats, caused an 11- to 18-fold increase in 
the  capacity of their  livers  to oxidize palmitoyl- 
coenzyme  A,  and  simultaneously  caused  an  in- 
crease  in  hepatic  peroxisomes  (20).  Recently, 
Lazarow reported that rat liver peroxisomes may 
be specialized for/3-oxidation of long-chain fatty 
acids (22). These reports shed new light not only 
on  a  mechanism  of  action  of Clofibrate,  tibric 
acid, and Wy-14,643 but also on the significance 
of peroxisome proliferation and the role of perox- 
isomes in lipid metabolism. In view of the chemi- 
cal structure of RMI 14,514 and its effects on the 
ultrastructure  and enzyme activity of hepatic per- 
oxisomes,  it  would  be  of interest  to  determine 
820  ThE  JOURNAL OF CELL BIOLOGY  ￿9  VOLUME 78, 1978 whether  RMI  14,514,  like  Clofibrate  and  other 
hypolipidemic drugs  unrelated  to  the  aryloxyiso- 
butyrate  group,  has  a  similar  effect  on  hepatic 
palmitoyl-coenzyme  A  oxidizing  activity.  Also, 
investigation of the effects of long-term adminis- 
tration  of RMI  14,514  and  serial studies after its 
withdrawal might prove informative. 
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